Manel Ben M'hadheb

Dr. Manel Ben M'hadheb


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2022 in Viruses
Verified
Journal Article
Open access
PDF file
IHIkbel Hadj Hassine
Ikbel Hadj Hassine
MMManel Ben M'hadheb
Manel Ben M'hadheb
Luis Menéndez-AriasLuis Menéndez-Arias
Luis Menéndez-Arias
In RNA viruses, a small increase in their mutation rates can be sufficient to exceed their threshold of viability. Lethal mutagenesis is a therapeutic strategy based on the use of mutagens, driving viral populations to extinction. Extinction catastrophe can be experimentally induced by promutagenic nucleosides in cell culture models. The loss of HIV infectivity has been observed after passage in 5-hydroxydeoxycytidine or 5,6-dihydro-5-aza-2′-deoxycytidine while producing a two-fold increase in the viral mutation frequency. Among approved nucleoside analogs, experiments with polioviruses and other RNA viruses suggested that ribavirin can be mutagenic, although its mechanism of action is not clear. Favipiravir and molnupiravir exert an antiviral effect through lethal mutagenesis. Both drugs are broad-spectrum antiviral agents active against RNA viruses. Favipiravir incorporates into viral RNA, affecting the G→A and C→U transition rates. Molnupiravir (a prodrug of β-d-N4-hydroxycytidine) has been recently approved for the treatment of SARS-CoV-2 infection. Its triphosphate derivative can be incorporated into viral RNA and extended by the coronavirus RNA polymerase. Incorrect base pairing and inefficient extension by the polymerase promote mutagenesis by increasing the G→A and C→U transition frequencies. Despite having remarkable antiviral action and resilience to drug resistance, carcinogenic risks and genotoxicity are important concerns limiting their extended use in antiviral therapy.

20 December 2023 in Reviews in Medical Virology
Verified
Journal Article
Closed access
IHIkbel Hadj Hassine
Ikbel Hadj Hassine
MMManel Ben M'hadheb
Manel Ben M'hadheb
MAMohammed A. Almalki
Mohammed A. Almalki
JGJawhar Gharbi
Jawhar Gharbi

18 March 2023 in Foods
Verified
Journal Article
Open access
PDF file
Hassiba ChahdouraHassiba Chahdoura
Hassiba Chahdoura
ZMZeineb Mzoughi
Zeineb Mzoughi
Ziani BorhaneZiani Borhane
Ziani Borhane
YCYasmine Chakroun
Yasmine Chakroun
MBMohamed Ali Boujbiha
Mohamed Ali Boujbiha
HMHabib Mosbah
Habib Mosbah
The goal of this work was to investigate the impact of the flavoring of some aromatic plants/spices, including rosemary (R), lemon (L) and orange (O) at the concentration of 5% and 35% (w/w) added by 2 methods (conventional maceration and direct flavoring), on quality attributes, chemical changes and oxidative stability of extra virgin olive oil (EVOO). Six flavored oils were obtained (EVOO + O, O + O, EVOO + R, O + R, EVOO + L and O + L). The physicochemical parameters (water content, refractive index, acidity and peroxide value, extinction coefficient, fatty acids, volatile aroma profiles, Rancimat test, phenols and pigments composition) of the flavored oils were investigated. Based on the results obtained, it was observed that flavoring with a conventional process provided increased oxidative stability to the flavored oils, especially with rosemary (19.38 ± 0.26 h), compared to that of unflavored oil. The volatile profiles of the different flavored oils revealed the presence of 34 compounds with the dominance of Limonene. The fatty acid composition showed an abundance of mono-unsaturated fatty acids followed by poly-unsaturated ones. Moreover, a high antioxidant activity, a significant peripheral analgesic effect (77.7% of writhing inhibition) and an interesting gastroprotective action (96.59% of ulcer inhibition) have been observed for the rosemary-flavored oil. Indeed, the flavored olive oils of this study could be used as new functional foods, leading to new customers and further markets.

17 April 2007 in Molecular Biotechnology
Verified
Journal Article
Closed access
PDF file
MMManel Ben M'hadheb
Manel Ben M'hadheb
SPSylvie Paulous
Sylvie Paulous
MAMahjoub Aouni
Mahjoub Aouni
KKKatherine M. Kean
Katherine M. Kean
JGJawhar Gharbi
Jawhar Gharbi

19 March 2024 in South African Journal of Botany
Verified
Journal Article
Closed access
HCHassiba Chahdoura
Hassiba Chahdoura
AHAnis Ben Hsouna
Anis Ben Hsouna
MBMohamed Ali Boujbiha
Mohamed Ali Boujbiha
WMWissem Mnif
Wissem Mnif
Mejdi SnoussiMejdi Snoussi
Mejdi Snoussi
HMHabib Mosbah
Habib Mosbah

17 September 2025 in Microorganisms
Verified
Journal Article
Open access
PDF file
LMLuca Maddaloni
Luca Maddaloni
GBGinevra Bugani
Ginevra Bugani
MFMatteo Fracella
Matteo Fracella
CBCamilla Bitossi
Camilla Bitossi
ADALESSANDRA D'AURIA
ALESSANDRA D'AURIA
CScarolina scagnolari
carolina scagnolari
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is recognized by pattern recognition receptors (PRRs), which play a vital role in triggering innate immune responses such as the production of type I and III interferons (IFNs). While modest PRR activation helps to defend against SARS-CoV-2, excessive or sustained activation can cause harmful inflammation and contribute to severe Coronavirus Disease 2019 (COVID-19). Altered expression of Toll-like receptors (TLRs), which are among the most important members of the PRR family members, particularly TLRs 2, 3, 4, 7, 8 and 9, has been strongly linked to COVID-19 severity. Furthermore, retinoic acid-inducible gene I (RIG-I) and melanoma differentiation-associated protein 5 (MDA5), collectively known as RLRs (RIG-I-like receptors), act as sensors that detect SARS-CoV-2 RNA. The expression of these receptors, as well as that of different DNA sensors, varies in patients infected with SARS-CoV-2. Changes in PRR expression, particularly that of TLRs, cyclic GMP-AMP synthase (cGAS), and the stimulator of interferon genes (STING), have also been shown to play a role in the development and persistence of long COVID (LC). However, SARS-CoV-2 has evolved strategies to evade PRR recognition and subsequent signaling pathway activation, contributing to the IFN response dysregulation observed in SARS-CoV-2-infected patients. Nevertheless, PRR agonists and antagonists remain promising therapeutic targets for SARS-CoV-2 infection. This review aims to describe the PRRs involved in recognizing SARS-CoV-2, explore their expression during SARS-CoV-2 infection, and examine their role in determining the severity of both COVID-19 and long-term manifestations of the disease. It also describes the strategies developed by SARS-CoV-2 to evade PRR recognition and activation. Moreover, given the considerable interest in modulating PRR activity as a novel immunotherapy approach, this review will provide a description of PRR agonists and antagonists that have been investigated as antiviral strategies against SARS-CoV-2. This review aims to explore the complex interplay between PRRs and SARS-CoV-2 in depth, considering its implications for prognostic biomarkers, targeted therapeutic strategies and the mechanistic understanding of long LC. Additionally, it outlines future perspectives that could help to address knowledge gaps in PRR-mediated responses during SARS-CoV-2 infection.